On April 7, 2023, the "Molecular Diagnostics Joint Laboratory" jointly built by the Key Laboratory of Medical Molecular Virology of Fudan University, Ministry of Education/Health and Health Commission/ Academy of Medical Sciences and Liferiver Bio-Tech.
This alliance is a new model of university-enterprise cooperation explored in the context of the national "innovation-driven development strategy" and "health China" strategy, and is a strategic cooperation based on the advantages and complementarity of basic research and product translation in the field of molecular diagnosis of infectious diseases, and the sense of responsibility for national major needs and social welfare.
With the joint efforts of both parties, the joint molecular diagnostic laboratory was accepted and put into clinical application in the early stage to carry out on-campus testing services for the convenience of teachers and students. In the future, both parties will also extend the existing foundation of molecular diagnostic testing capability to a broader direction, carry out project cooperation in the field of basic and translational research of various pathogen detection, and join hands to carry out public welfare services. Based on the foundation of this university-enterprise cooperation project, the two sides will also jointly conduct joint enrollment of engineering doctorate to cultivate professional field talents with comprehensive ability of integrating research and industrial transformation, so that enterprises can obtain intellectual support and technological innovation from universities, and students can also obtain more practical opportunities to enhance their innovation ability.
Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.